In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes

Dabour, Nassra; Zihler, Annina; Kheadr, Ehab; Lacroix, Christophe; Fliss, Ismaı̈l

doi:10.1016/j.ijfoodmicro.2009.05.005

Cited by 106 publications

(79 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…in vitro, a corresponding effect was not observed in vivo (13). In this instance, the intragastric administration of 10 10 CFU/animal of P. acidilactici UL5 failed to provide protection against L. monocytogenes infection in mice, despite the fact that the administration of purified pediocin PA-1 to mice resulted in a ca.…”

Section: Bacteriocin Function: An Ecological Perspectivementioning

confidence: 83%

Bacteriocin Production: a Probiotic Trait?

Dobson

Cotter

Ross

et al. 2012

Appl Environ Microbiol

559

368

View full text Add to dashboard Cite

Bacteriocins are an abundant and diverse group of ribosomally synthesized antimicrobial peptides produced by bacteria and archaea. Traditionally, bacteriocin production has been considered an important trait in the selection of probiotic strains, but until recently, few studies have definitively demonstrated the impact of bacteriocin production on the ability of a strain to compete within complex microbial communities and/or positively influence the health of the host. Although research in this area is still in its infancy, there is intriguing evidence to suggest that bacteriocins may function in a number of ways within the gastrointestinal tract. Bacteriocins may facilitate the introduction of a producer into an established niche, directly inhibit the invasion of competing strains or pathogens, or modulate the composition of the microbiota and influence the host immune system. Here we review the role of bacteriocin production in complex microbial communities and their potential to enhance human health.

show abstract

Section: Bacteriocin Function: An Ecological Perspectivementioning

confidence: 83%

Bacteriocin Production: a Probiotic Trait?

Dobson

Cotter

Ross

et al. 2012

Appl Environ Microbiol

559

368

View full text Add to dashboard Cite

show abstract

“…Antagonistic activity of the bacteriocin producers against a number of pathogenic or antibiotic-resistant bacterial strains in the gut has been a major focus of gut microbiota studies. Several LAB bacteriocins and/or bacteriocin-producing LAB have been shown to inhibit pathogens such as Listeria monocytogenes [83,84], Clostridium difficile [85–87], Staphylococcus aureus [88] and even Salmonella enteritidis [89], Some bacteriocin producers have also been reported to eliminate multidrug- or vancomycin-resistant enterococci [81,90]. Therefore, the production of bacteriocins may contribute to the beneficial activities in the gut.…”

Section: Bacteriocinsmentioning

confidence: 99%

Modulation of the gut microbiota by prebiotic fibres and bacteriocins

Umu

Rudi

Diep

2017

Microbial Ecology in Health and Disease

View full text Add to dashboard Cite

The gut microbiota is considered an organ that co-develops with the host throughout its life. The composition and metabolic activities of the gut microbiota are subject to a complex interplay between the host genetics and environmental factors, such as lifestyle, diet, stress and antimicrobials. It is evident that certain prebiotics, and antimicrobials produced by lactic acid bacteria (LAB), can shape the composition of the gut microbiota and its metabolic activities to promote host health and/or prevent diseases. In this review, we aim to give an overview of the impact of prebiotic fibres, and bacteriocins from LAB, on the gut microbiota and its activities, which affect the physiology and health of the host. These represent two different mechanisms in modulating the gut microbiota, the first involving exploitative competition by which the growth of beneficial bacteria is promoted and the latter involving interference competition by which the growth of pathogens and other unwanted bacteria is prevented. For interference competition in the gut, bacteriocins offer special advantages over traditional antibiotics, in that they can be designed to act towards specific unwanted bacteria and other pathogens, without any remarkable collateral effects on beneficial microbes sharing the same niche.

show abstract

“…Corr et al (2007), for example, showed that Lactobacillus salivarius UCC118 is able to produce the bacteriocin Abp118 in vivo, resulting in the protection of mice against Listeria monocytogenes infection. Using an ICR mouse model infected with Listeria, Dabour et al (2009) recently showed that intragastric administration of repeated doses of pediocin PA-1 reduces Listeria counts and pathogen translocation into the liver and spleen compared with the infected control group, leading to the disappearance of L. monocytogenes in these two organs within 6 days. However, enteric protection related to in situ bacteriocin production in human gut environments has been little studied.…”

Section: Introductionmentioning

confidence: 99%

Unexpected consequences of administering bacteriocinogenic probiotic strains for Salmonella populations, revealed by an in vitro colonic model of the child gut

et al. 2010

Self Cite

View full text Add to dashboard Cite

New biological strategies for the treatment of Salmonella infection are needed in response to the increase in antibiotic-resistant strains. Escherichia coli L1000 and Bifidobacterium thermophilum RBL67 were previously shown to produce antimicrobial proteinaceous compounds (microcin B17 and thermophilicin B67, respectively) active in vitro against a panel of Salmonella strains recently isolated from clinical cases in Switzerland. In this study, two three-stage intestinal continuous fermentation models of Salmonella colonization inoculated with immobilized faeces of a two-year-old child were implemented to study the effects of the two bacteriocinogenic strains compared with a bacteriocin-negative mutant of strain L1000 on Salmonella growth, as well as gut microbiota composition and metabolic activity. Immobilized E. coli L1000 added to the proximal colon reactor showed a low colonization, and developed preferentially in the distal colon reactor independent of the presence of genetic determinants for microcin B17 production. Surprisingly, E. coli L1000 addition strongly stimulated Salmonella growth in all three reactors. In contrast, B. thermophilum RBL67 added in a second phase stabilized at high levels in all reactors, but could not inhibit Salmonella already present at a high level (>107 c.f.u. ml−1) when the probiotic was added. Inulin added at the end of fermentation induced a strong bifidogenic effect in all three colon reactors and a significant increase of Salmonella counts in the distal colon reactor. Our data show that under the simulated child colonic conditions, the microcin B17 production phenotype does not correlate with inhibition of Salmonella but leads to a better colonization of E. coli L1000 in the distal colon reactor. We conclude that in vitro models with complex and complete gut microbiota are required to accurately assess the potential and efficacy of probiotics with respect to Salmonella colonization in the gut.

show abstract

In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes

Cited by 106 publications

References 38 publications

Bacteriocin Production: a Probiotic Trait?

Bacteriocin Production: a Probiotic Trait?

Modulation of the gut microbiota by prebiotic fibres and bacteriocins

Unexpected consequences of administering bacteriocinogenic probiotic strains for Salmonella populations, revealed by an in vitro colonic model of the child gut

Contact Info

Product

Resources

About